Daichi Fujimoto

10PUBLICATIONS
48CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCondensed matter physics not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Jan 05, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio, Shuji Murakami, Hisato Kawakami

|Oct 21, 2022
Histologic transformation in lung cancer: when one door shuts, another opens.

Yuki Sato, Go Saito, Daichi Fujimoto

|Aug 22, 2022
Radiographic findings useful for diagnosis of primary chest wall lymphoma without preceding pleural disease: A case report.

Masanori Tanaka, Daichi Fujimoto, Hiroaki Akamatsu

|Mar 29, 2021
Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature.

Mihoko Imaji, Daichi Fujimoto, Mai Kato

|Jan 06, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.

Takeya Sugimoto, Daichi Fujimoto, Yuki Sato

Pageof 2

Frequent Collaborators

1 joint publications

Masanori Tanaka

1 joint publications

Makoto Nishio

1 joint publications

Shuji Murakami

1 joint publications

Hisato Kawakami